-+ 0.00%
-+ 0.00%
-+ 0.00%

PCI Biotech to Shut Down Research, Development Operations; Liquidity Position 'Critical'

MT Newswires·01/08/2026 11:01:42
Listen to the news
11:01 AM EST, 01/08/2026 (MT Newswires) -- PCI Biotech (PCIB.OL) will discontinue its entire research and development operations after concluding its external evaluation of a new bioprocessing technology with no collaboration prospects. The Norwegian biopharmaceutical company said Thursday it continues to explore strategic alternatives, including a merger or a structured wind-up of the business, amid its "critical" liquidity position and uncertainty in securing additional funding.